

March 18, 2019



## **Soliton to Present at Oppenheimer 29th Annual Healthcare Conference on March 20, 2019**

HOUSTON, March 18, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), has been invited to present at Oppenheimer's 29<sup>th</sup> Annual Healthcare Conference on Wednesday, March 20, 2019 at The Westin New York Grand Central in New York City. The conference is one of the most important investor conferences in the medical device industry, as well as other healthcare related industries.



"We are proud to have been invited to present to investors at this prestigious conference," said Dr. Chris Capelli, Soliton's President and CEO. "To be included amongst the thought leaders and innovators in this sector is indeed an honor. We believe the discussion of our Rapid Acoustic Pulse (RAP) technology used to target tattoo removal and our newer related technology that has the potential to treat cellulite, our compelling clinical data, and our recent IPO will be a highlight of the conference."

### **About Soliton, Inc.**

Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from MD Anderson. The Company's first planned commercial product is designed to use rapid pulses of designed acoustic shockwaves in conjunction with existing lasers to accelerate the removal of unwanted tattoos (RAP device). In addition, higher energy versions of acoustic pulse devices are in early stages of development for potential stand-alone treatment of cellulite and other indications. Both products are investigational and are not available for sale in the United States.

For more information about the Company, please visit: <http://www.soliton.com>

## Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the ability of Soliton RAP to receive FDA clearance. These statements relate to future events, future expectations, plans and prospects. Although Soliton believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Soliton has attempted to identify forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under in our SEC filings, including under the heading "Risk Factors" in the Form 1-A we filed with the SEC on February 13, 2019. Any forward-looking statements contained in this release speak only as of its date. Soliton undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

### CONTACT:

**Joe Dorame, Joe Diaz & Robert Blum**  
**Lytham Partners, LLC**  
**602-889-9700**  
[soly@lythampartners.com](mailto:soly@lythampartners.com)

View original content to download multimedia <http://www.prnewswire.com/news-releases/soliton-to-present-at-oppenheimer-29th-annual-healthcare-conference-on-march-20-2019-300813664.html>

SOURCE Soliton, Inc.